Vittoria Biotherapeutics, Inc. Employee Directory
Biotechnology ResearchPennsylvania, United States11-50 Employees
Vittoria Biotherapeutics, Inc. operates in biotechnology research with a focus on cell therapies, aiming to strengthen efficacy and safety while expanding use cases for patients with difficult-to-treat diseases. The company is active in developing CAR T cell therapies, including VIPER-101, an autologous T-cell therapy for lymphoma. This work situates Vittoria within the immuno-oncology field, addressing limitations of current cellular treatments. The firm is based in Philadelphia, Pennsylvania, and is described as a clinical-stage biotechnology company. In 2024 it shared preclinical data at the ASH meeting on its CD5-modulating Senza5 platform, and in 2025 it received the Startup of the Year Award at the Penn Center for Innovation's Celebration of Innovation.